Backenroth Samuel 4
4 · NeuBase Therapeutics, Inc. · Filed May 4, 2020
Insider Transaction Report
Form 4
Backenroth Samuel
CEO & VP of Bus. Development
Transactions
- Purchase
Common Stock
2020-04-30$6.00/sh+1,000$6,000→ 11,630 total
Footnotes (1)
- [F1]The power of attorney under which this form was signed is on file with the Commission.